# 2026-05573: FDA's VIP Pass for Urgent Drugs: Hearing Seeks Public Input

2026-05573, Commissioner's National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-23, effective The public hearing will be held with an in-person and virtual option (i.e., hybrid) on June 12, 2026, from 1:00 p.m. to 4:00 p.m. Eastern Time. Meeting registration, including requests for participation in the public hearing, can be found at the following website: https://www/fda.gov/news-events/commissioners-national- priority-voucher-cnpv-pilot-program-public-hearing-06122026. All requests for participation, including for those who wish to present during the public hearing, must be received by 11:59 p.m., May 1, 2026, through the meeting registration page. Questions about meeting registration and participation should be sent to CommissionerVoucher@fda.hhs.gov, and include the title of this notice: "Commissioner's National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments"). See the SUPPLEMENTARY INFORMATION section for attendance and registration information.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-05573
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05573
- Title: Commissioner's National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 13849
- Published: 2026-03-23
- Effective: The public hearing will be held with an in-person and virtual option (i.e., hybrid) on June 12, 2026, from 1:00 p.m. to 4:00 p.m. Eastern Time. Meeting registration, including requests for participation in the public hearing, can be found at the following website: https://www/fda.gov/news-events/commissioners-national- priority-voucher-cnpv-pilot-program-public-hearing-06122026. All requests for participation, including for those who wish to present during the public hearing, must be received by 11:59 p.m., May 1, 2026, through the meeting registration page. Questions about meeting registration and participation should be sent to CommissionerVoucher@fda.hhs.gov, and include the title of this notice: "Commissioner's National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments"). See the SUPPLEMENTARY INFORMATION section for attendance and registration information.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA's VIP Pass for Urgent Drugs: Hearing Seeks Public Input

## Summary

The FDA is launching a pilot program called the Commissioner's National Priority Voucher (CNPV) to speed up reviews for important new drugs and treatments that tackle big U.S. health challenges. They’re inviting drug makers, experts, and the public to a hearing on June 12, 2026, to share ideas and feedback on how the program should work. This could mean faster approvals and quicker access to life-saving medicines without cutting corners.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is announcing a public hearing related to the Commissioner's National Priority Voucher (CNPV) Pilot Program, which is designed to significantly reduce review times for qualifying new drug applications (NDAs), biologics license applications (BLAs), and manufacturing or efficacy supplements through enhanced regulatory engagement and streamlined review procedures. The CNPV Pilot Program is intended to expedite approvals for products that align with critical U.S. national health priorities while maintaining FDA's rigorous scientific and regulatory standards. We are holding this public hearing to obtain feedback and perspectives regarding the CNPV Pilot Program, including feedback on the eligibility criteria, voucher selection processes, sponsor responsibilities, FDA review procedures, and program implementation.

## Effects PRIA read

- Ultra-fast FDA review target: benefit, high. The CNPV Pilot Program aims to cut FDA review times for qualifying NDAs, BLAs, and supplements from the typical 10–12 months to a target of 1–2 months. FDA also proposes a filing review target of 14–21 days after receipt of the final application component.
- Priority areas that qualify: benefit, medium. The program is limited to products that align with specified national priorities: public health crisis response; innovative breakthrough therapies; large unmet medical needs; onshoring and supply chain resilience; and affordability improvements. Only NDAs, BLAs, and manufacturing or efficacy supple…
- Nontransferable voucher rule: cost, medium. CNPV vouchers are nontransferable: they cannot be sold or used for a different application, unlike some traditional priority review vouchers. The voucher grants expedited review for a single application to its recipient only.
- Rapid sponsor response and meeting demands: cost, medium. Sponsors accepting a CNPV voucher are expected to respond rapidly to FDA information requests (typically within 24–48 hours), be available for ad hoc meetings during business hours, and facilitate inspections. Labeling negotiations are envisioned to be limited to a maximum of two rounds.
- Presubmission, rolling, and submission deadlines: cost, medium. The program asks for presubmission meetings, rolling submissions of CMC information and proposed labeling at least 60 days before final module submission, and recommends limiting manufacturing facilities to no more than 2–3 per submission (with justification required for more). Sponsors are expecte…
- Eligibility excludes most medical devices: cost, low. Medical device applications are excluded from the CNPV Pilot Program, though combination products with a drug or biological product primary mode of action may be eligible. The program focuses on drug and biologic applications (NDAs and BLAs) and certain supplements.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-05573 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/23/2026-05573/commissioners-national-priority-voucher-cnpv-pilot-program-public-hearing-request-for-comments)
- [2026-05573 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-23/pdf/2026-05573.pdf)

## Related
- [Previous: 2026-05572, Foreign-Trade Zone 27; Application for Subzone; Methods Machine Tools, Inc.; Ac…](https://policyrisk.com/federal-register/2026-05572)
- [Next: 2026-05575, Announcement of Public Hearing](https://policyrisk.com/federal-register/2026-05575)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05573 (as of 2026-06-08).
